PTC Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . PTC Therapeutics
PTCT Stock  USD 55.47  1.70  2.97%   
PTC Therapeutics financial statements provide useful quarterly and yearly information to potential PTC Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on PTC Therapeutics financial statements helps investors assess PTC Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PTC Therapeutics' valuation are summarized below:
Gross Profit
214.9 M
Profit Margin
(0.45)
Market Capitalization
4.5 B
Enterprise Value Revenue
6.9781
Revenue
806.8 M
There are currently one hundred twenty fundamental measures for PTC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should check out PTC Therapeutics' latest fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.6 B in 2025. Enterprise Value is likely to gain to about 3.2 B in 2025

PTC Therapeutics Total Revenue

847.12 Million

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 175.3 M, Total Revenue of 847.1 M or Research Development of 270.7 M, as well as many indicators such as Price To Sales Ratio of 4.08, Dividend Yield of 0.0 or Days Sales Outstanding of 52.14. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of PTC Therapeutics Correlation against competitors.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

PTC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets952.2 M1.7 B922.4 M
Slightly volatile
Other Current Liabilities553.1 M526.8 M158.8 M
Slightly volatile
Total Current Liabilities610 M581 M230.5 M
Slightly volatile
Other Liabilities263.2 M309.9 M262 M
Slightly volatile
Accounts Payable10.5 M17.3 M10.1 M
Slightly volatile
Cash818.7 M779.7 M351.9 M
Slightly volatile
Other Assets40.3 M38.4 M17.2 M
Slightly volatile
Short Term Investments289.8 M360 M262.8 M
Slightly volatile
Total Liabilities2.9 B2.8 B1 B
Slightly volatile
Property Plant Equipment87.7 M83.5 M36.2 M
Slightly volatile
Short and Long Term Debt Total439.9 M389.3 M364.8 M
Slightly volatile
Property Plant And Equipment Net63.9 M117.7 M55.5 M
Slightly volatile
Current Deferred Revenue5.2 M5.5 M23 M
Pretty Stable
Non Current Assets Total472.3 M339.5 M405.9 M
Slightly volatile
Non Currrent Assets Other34 M20.7 M29.2 M
Slightly volatile
Cash And Short Term Investments1.2 B1.1 B480.9 M
Slightly volatile
Net Receivables166.5 M158.6 M64.4 M
Slightly volatile
Common Stock Total Equity45.3 K82.8 K43.4 K
Slightly volatile
Common Stock Shares Outstanding52.2 M76.8 M46.2 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.7 B930.8 M
Slightly volatile
Non Current Liabilities Total2.3 B2.2 B822.5 M
Slightly volatile
Property Plant And Equipment Gross75.7 M151 M65.6 M
Slightly volatile
Total Current Assets1.4 B1.4 B576.4 M
Slightly volatile
Short Term Debt25.4 M26.7 M50 M
Slightly volatile
Common Stock50.8 K77 K43.6 K
Slightly volatile
Capital Surpluse1.6 B2.7 B1.3 B
Slightly volatile
Non Current Liabilities Other20.4 M21.4 M234.1 M
Slightly volatile
Long Term Debt Total690.4 M657.5 M270.5 M
Slightly volatile
Short and Long Term Debt270.7 M257.8 M120 M
Slightly volatile
Net Invested Capital785.2 M1.3 B537.9 M
Slightly volatile
Net Working Capital543.3 M784.5 M354 M
Slightly volatile
Capital Stock75.1 K77 K60.1 K
Slightly volatile
Capital Lease Obligations128 M103.9 M113.9 M
Slightly volatile

PTC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue847.1 M806.8 M329.9 M
Slightly volatile
Research Development270.7 M534.5 M261.7 M
Slightly volatile
Depreciation And Amortization54.4 M75.7 M46.9 M
Slightly volatile
Selling General Administrative175.8 M300.9 M151.9 M
Slightly volatile
Other Operating Expenses557 M1.1 B482.1 M
Slightly volatile
Total Operating Expenses1.2 B1.1 B513.8 M
Slightly volatile
Interest Income10.5 M14.4 M8.4 M
Slightly volatile
Reconciled Depreciation80.1 M75.7 M49.2 M
Slightly volatile
Non Recurring26.7 M30 M32.8 M
Slightly volatile

PTC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures6.2 M6.5 M31.4 M
Slightly volatile
End Period Cash Flow835.1 M795.3 M235.5 M
Slightly volatile
Stock Based Compensation54.8 M74.6 M47.2 M
Slightly volatile
Begin Period Cash Flow640.8 M610.3 M175.5 M
Slightly volatile
Depreciation53.6 M75.7 M46.2 M
Slightly volatile
Other Non Cash Items46.4 M58.7 M39.8 M
Slightly volatile
Sale Purchase Of Stock89.2 M64 M119.8 M
Slightly volatile
Change To Netincome79 M130.8 M67.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.084.299510.8738
Pretty Stable
Days Sales Outstanding52.1471.732360.5766
Slightly volatile
Average Payables2.1 M2.4 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.08790.09250.2418
Pretty Stable
Capex To Depreciation0.08160.08590.634
Pretty Stable
EV To Sales3.623.81569.4154
Pretty Stable
Inventory Turnover1.041.930.9395
Slightly volatile
Days Of Inventory On Hand186196573
Slightly volatile
Sales General And Administrative To Revenue0.80.520.7764
Very volatile
Research And Ddevelopement To Revenue0.630.66251.2525
Slightly volatile
Capex To Revenue0.00770.00810.0766
Slightly volatile
Cash Per Share9.3514.831110.9343
Slightly volatile
Intangibles To Total Assets0.110.1180.351
Pretty Stable
Current Ratio4.352.35043.7788
Pretty Stable
Receivables Turnover4.835.088417.2976
Slightly volatile
Capex Per Share0.08040.08460.4706
Slightly volatile
Average Receivables1.2 M1.1 M1 M
Very volatile
Revenue Per Share11.0210.49885.9839
Slightly volatile
Interest Debt Per Share4.857.23915.6717
Slightly volatile
Debt To Assets0.260.22830.3108
Slightly volatile
Operating Cycle68.1571.7323236
Pretty Stable
Ebt Per Ebit0.951.20011.1561
Slightly volatile
Quick Ratio4.32.31053.7412
Pretty Stable
Net Income Per E B T1.11.00051.0088
Very volatile
Cash Ratio1.271.34212.3698
Pretty Stable
Days Of Inventory Outstanding186196573
Slightly volatile
Days Of Sales Outstanding52.1471.732360.5766
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.991.06041.2098
Slightly volatile
Fixed Asset Turnover9.176.85728.4458
Very volatile
Debt Ratio0.260.22830.3108
Slightly volatile
Price Sales Ratio4.084.299510.8738
Pretty Stable
Asset Turnover0.620.47320.671
Slightly volatile

PTC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.6 B3.5 B1.7 B
Slightly volatile
Enterprise Value3.2 B3.1 B1.7 B
Slightly volatile

PTC Fundamental Market Drivers

Forward Price Earnings20.3666
Cash And Short Term Investments1.1 B

PTC Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.5 M5.2 M
Total Revenue806.8 M847.1 M
Cost Of Revenue57.4 M37.1 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 0.52  0.80 
Research And Ddevelopement To Revenue 0.66  0.63 
Capex To Revenue 0.01  0.01 
Revenue Per Share 10.50  11.02 
Ebit Per Revenue(0.38)(0.39)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY